Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy
| العنوان: | Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy |
|---|---|
| المؤلفون: | Giancarlo Comi, Hugh J. Willison, Costas Kilindireas, Richard A. C. Hughes, Paul McCrone, Isabel Illa, A. V. Swan, Martin Knapp, Marinos C. Dalakas, Daniel Chisholm, Peter Van den Bergh, Eduardo Nobile-Orazio |
| المصدر: | European Journal of Neurology. 10:687-694 |
| بيانات النشر: | Wiley, 2003. |
| سنة النشر: | 2003 |
| مصطلحات موضوعية: | Cost–utility analysis, medicine.medical_specialty, Pediatrics, business.industry, Polyradiculoneuropathy, Cost-effectiveness analysis, medicine.disease, Crossover study, Quality-adjusted life year, Neurology, Quality of life, hemic and lymphatic diseases, Economic evaluation, medicine, Physical therapy, Prednisolone, Neurology (clinical), business, health care economics and organizations, medicine.drug |
| الوصف: | The aim of this study was to provide an incremental cost-effectiveness analysis comparing intravenous immunoglobulin (IVIg) and prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy. Patients were recruited to a double-blind randomized crossover trial from nine European centres and received either prednisolone or IVIg during the first 6-week treatment period on which the economic evaluation was based. A societal perspective was adopted in measuring service use and costs, although the costs of lost employment were not included. The main outcome measure in the economic evaluation was the number of quality adjusted life years (QALYs) gained, with change in a 11-point disability scale used to measure clinical outcomes. Service use and quality of life data were available for 25 patients. Baseline costs were controlled for using a bootstrapped multiple regression model. The cost difference between the two treatments was estimated to be e3754 over the 6-week period. Health-related quality of life, as measured by the EuroQol EQ-5D instrument, increased more in the IVIg group but the difference was not statistically significant. Using a net-benefit approach it was shown that the probability of IVIg being cost-effective in comparison with prednisolone was 0.5 or above (i.e. was more likely to be cost-effective than cost-ineffective) only if one QALY was valued at over e250 000. The cost-effectiveness of IVIg is greatly affected by the price of IVIg and the amount administered. The impact of later side-effects of prednisolone on long-term costs and quality of life are likely to reduce the cost per QALY of IVIg treatment. |
| تدمد: | 1351-5101 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::832a40be253757fcb409688418f81378Test https://doi.org/10.1046/j.1351-5101.2003.00701.xTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi...........832a40be253757fcb409688418f81378 |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.doi...........832a40be253757fcb409688418f81378 784 3 unknown 784.136840820313 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........832a40be253757fcb409688418f81378&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
|
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Giancarlo+Comi%22">Giancarlo Comi</searchLink><br /><searchLink fieldCode="AR" term="%22Hugh+J%2E+Willison%22">Hugh J. Willison</searchLink><br /><searchLink fieldCode="AR" term="%22Costas+Kilindireas%22">Costas Kilindireas</searchLink><br /><searchLink fieldCode="AR" term="%22Richard+A%2E+C%2E+Hughes%22">Richard A. C. Hughes</searchLink><br /><searchLink fieldCode="AR" term="%22Paul+McCrone%22">Paul McCrone</searchLink><br /><searchLink fieldCode="AR" term="%22Isabel+Illa%22">Isabel Illa</searchLink><br /><searchLink fieldCode="AR" term="%22A%2E+V%2E+Swan%22">A. V. Swan</searchLink><br /><searchLink fieldCode="AR" term="%22Martin+Knapp%22">Martin Knapp</searchLink><br /><searchLink fieldCode="AR" term="%22Marinos+C%2E+Dalakas%22">Marinos C. Dalakas</searchLink><br /><searchLink fieldCode="AR" term="%22Daniel+Chisholm%22">Daniel Chisholm</searchLink><br /><searchLink fieldCode="AR" term="%22Peter+Van+den+Bergh%22">Peter Van den Bergh</searchLink><br /><searchLink fieldCode="AR" term="%22Eduardo+Nobile-Orazio%22">Eduardo Nobile-Orazio</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <i>European Journal of Neurology</i>. 10:687-694 ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Wiley, 2003. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2003 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Cost–utility+analysis%22">Cost–utility analysis</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Emedical%5Fspecialty%22">medicine.medical_specialty</searchLink><br /><searchLink fieldCode="DE" term="%22Pediatrics%22">Pediatrics</searchLink><br /><searchLink fieldCode="DE" term="%22business%2Eindustry%22">business.industry</searchLink><br /><searchLink fieldCode="DE" term="%22Polyradiculoneuropathy%22">Polyradiculoneuropathy</searchLink><br /><searchLink fieldCode="DE" term="%22Cost-effectiveness+analysis%22">Cost-effectiveness analysis</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edisease%22">medicine.disease</searchLink><br /><searchLink fieldCode="DE" term="%22Crossover+study%22">Crossover study</searchLink><br /><searchLink fieldCode="DE" term="%22Quality-adjusted+life+year%22">Quality-adjusted life year</searchLink><br /><searchLink fieldCode="DE" term="%22Neurology%22">Neurology</searchLink><br /><searchLink fieldCode="DE" term="%22Quality+of+life%22">Quality of life</searchLink><br /><searchLink fieldCode="DE" term="%22hemic+and+lymphatic+diseases%22">hemic and lymphatic diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Economic+evaluation%22">Economic evaluation</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%22">medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Physical+therapy%22">Physical therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Prednisolone%22">Prednisolone</searchLink><br /><searchLink fieldCode="DE" term="%22Neurology+%28clinical%29%22">Neurology (clinical)</searchLink><br /><searchLink fieldCode="DE" term="%22business%22">business</searchLink><br /><searchLink fieldCode="DE" term="%22health+care+economics+and+organizations%22">health care economics and organizations</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edrug%22">medicine.drug</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => The aim of this study was to provide an incremental cost-effectiveness analysis comparing intravenous immunoglobulin (IVIg) and prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy. Patients were recruited to a double-blind randomized crossover trial from nine European centres and received either prednisolone or IVIg during the first 6-week treatment period on which the economic evaluation was based. A societal perspective was adopted in measuring service use and costs, although the costs of lost employment were not included. The main outcome measure in the economic evaluation was the number of quality adjusted life years (QALYs) gained, with change in a 11-point disability scale used to measure clinical outcomes. Service use and quality of life data were available for 25 patients. Baseline costs were controlled for using a bootstrapped multiple regression model. The cost difference between the two treatments was estimated to be e3754 over the 6-week period. Health-related quality of life, as measured by the EuroQol EQ-5D instrument, increased more in the IVIg group but the difference was not statistically significant. Using a net-benefit approach it was shown that the probability of IVIg being cost-effective in comparison with prednisolone was 0.5 or above (i.e. was more likely to be cost-effective than cost-ineffective) only if one QALY was valued at over e250 000. The cost-effectiveness of IVIg is greatly affected by the price of IVIg and the amount administered. The impact of later side-effects of prednisolone on long-term costs and quality of life are likely to reduce the cost per QALY of IVIg treatment. ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1351-5101 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_________::832a40be253757fcb409688418f81378" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_________::832a40be253757fcb409688418f81378</link><br /><link linkTarget="URL" linkTerm="https://doi.org/10.1046/j.1351-5101.2003.00701.x" linkWindow="_blank">https://doi.org/10.1046/j.1351-5101.2003.00701.x</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => OPEN ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi...........832a40be253757fcb409688418f81378 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => Undetermined
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 8
[StartPage] => 687
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Cost–utility analysis
[Type] => general
)
[1] => Array
(
[SubjectFull] => medicine.medical_specialty
[Type] => general
)
[2] => Array
(
[SubjectFull] => Pediatrics
[Type] => general
)
[3] => Array
(
[SubjectFull] => business.industry
[Type] => general
)
[4] => Array
(
[SubjectFull] => Polyradiculoneuropathy
[Type] => general
)
[5] => Array
(
[SubjectFull] => Cost-effectiveness analysis
[Type] => general
)
[6] => Array
(
[SubjectFull] => medicine.disease
[Type] => general
)
[7] => Array
(
[SubjectFull] => Crossover study
[Type] => general
)
[8] => Array
(
[SubjectFull] => Quality-adjusted life year
[Type] => general
)
[9] => Array
(
[SubjectFull] => Neurology
[Type] => general
)
[10] => Array
(
[SubjectFull] => Quality of life
[Type] => general
)
[11] => Array
(
[SubjectFull] => hemic and lymphatic diseases
[Type] => general
)
[12] => Array
(
[SubjectFull] => Economic evaluation
[Type] => general
)
[13] => Array
(
[SubjectFull] => medicine
[Type] => general
)
[14] => Array
(
[SubjectFull] => Physical therapy
[Type] => general
)
[15] => Array
(
[SubjectFull] => Prednisolone
[Type] => general
)
[16] => Array
(
[SubjectFull] => Neurology (clinical)
[Type] => general
)
[17] => Array
(
[SubjectFull] => business
[Type] => general
)
[18] => Array
(
[SubjectFull] => health care economics and organizations
[Type] => general
)
[19] => Array
(
[SubjectFull] => medicine.drug
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Giancarlo Comi
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hugh J. Willison
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Costas Kilindireas
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Richard A. C. Hughes
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Paul McCrone
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Isabel Illa
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => A. V. Swan
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Martin Knapp
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Marinos C. Dalakas
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Daniel Chisholm
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Peter Van den Bergh
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Eduardo Nobile-Orazio
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 22
[M] => 10
[Type] => published
[Y] => 2003
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 13515101
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsair
)
[2] => Array
(
[Type] => issn-locals
[Value] => edsairFT
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 10
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => European Journal of Neurology
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |